Orgenesis Inc. (ORGS) Income Statement
ORGS 2024 at a glance
Fiscal year ended December 31, 2024 · U.S. dollarsORGS revenue and net income
Where ORGS's revenue goes
2024Each bar shows an amount and its share of revenue. ORGS kept −4,653.6% of revenue as net income.
ORGS profit margins
ORGS growth rates
to 2024| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +95.3% | −69.2% | −50.0% | −10.0% |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ORGS quarterly EPS vs estimates
Orgenesis beat the analyst EPS estimate in 0 of the last 8 quarters.
ORGS income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $530,000 | $36.0M | $35.5M | $7.7M | $33.3M | $18.7M | $18.7M | $10.1M | $6.4M |
| Cost of revenue | $9.5M | $6.3M | $20.4M | $28.2M | $31.1M | $18.1M | $10.7M | $10.7M | $6.8M | $7.7M |
| Gross profit | −$8.5M | −$5.7M | $15.6M | $7.3M | −$23.4M | $15.1M | $8.0M | $8.0M | $3.3M | −$1.3M |
| Research & development | $3.8M | $11.1M | $6.0M | $36.6M | $84.0M | $12.5M | $6.5M | $6.5M | $2.5M | $2.2M |
| Sales, general & admin | $12.9M | $35.1M | $16.7M | $15.4M | $19.7M | $26.4M | $16.6M | $16.6M | $11.3M | $6.8M |
| Total operating expenses | $27.1M | $47.9M | $23.0M | $50.0M | $103.4M | $39.7M | $22.1M | $22.1M | $14.8M | $10.2M |
| Operating income | −$26.1M | −$53.6M | −$7.5M | −$16.8M | −$95.8M | −$24.6M | −$14.7M | −$14.7M | −$11.2M | $11.3M |
| Interest income | — | — | — | — | — | $1.1M | $35,000 | $2.9M | $2.1M | $1.2M |
| Interest expense | $3.7M | $2.2M | $1.8M | $369,000 | $1.1M | $461,000 | $2.8M | $2.8M | $1.2M | $689,000 |
| Income before taxes | −$48.9M | −$64.4M | −$12.0M | −$18.0M | −$96.7M | −$25.5M | −$17.8M | −$17.8M | −$13.7M | −$10.7M |
| Income taxes | — | $473,000 | $209,000 | $108,000 | −$1.6M | $563,000 | $1.3M | $1.3M | −$1.3M | −$1.5M |
| Net income | −$48.2M | −$55.4M | −$14.9M | −$18.1M | −$95.8M | −$26.0M | −$18.3M | −$18.3M | −$12.4M | −$9.2M |
| EBITDA | −$43.1M | −$60.7M | −$8.2M | −$15.7M | −$94.2M | −$18.9M | −$12.4M | −$12.2M | −$9.8M | −$9.0M |
| EPS (diluted) | −$9.31 | −$1.75 | −$5.46 | −$5.61 | −$3.58 | −$9.51 | −$1.47 | −$1.27 | −$0.78 | −$19.83 |
| Gross margin | −818.6% | −1,080.2% | 43.3% | 20.7% | −306.4% | 45.5% | 42.7% | 42.7% | 32.5% | −19.7% |
| Operating margin | −2,518.4% | −10,120.0% | −20.9% | −47.3% | −1,251.7% | −74.0% | −78.5% | −78.5% | −111.3% | 176.3% |
| Net margin | −4,653.6% | −10,445.5% | −41.3% | −50.9% | −1,252.1% | −78.3% | −98.0% | −98.0% | −122.6% | −143.7% |
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $301,000 | $347,000 | $246,000 | $141,000 | $0 | $110,000 | $7.0M | $7.0M | $13.6M | $8.0M | $7.2M | $7.2M |
| Cost of revenue | −$490,000 | $585,000 | $995,000 | $758,000 | $162,000 | $139,000 | $3.2M | $2.7M | −$51,000 | $4.5M | $8.8M | $714,000 |
| Gross profit | $791,000 | −$238,000 | −$749,000 | −$617,000 | −$13.8M | −$29,000 | $3.7M | $4.3M | $13.7M | $3.4M | −$1.5M | $6.5M |
| Research & development | $2.6M | $4.3M | $1.3M | $2.3M | $3.0M | $808,000 | $3.7M | $3.5M | $27.1M | $114,000 | $8.9M | $6.7M |
| Sales, general & admin | $6.2M | $2.7M | $2.1M | $6.0M | $26.5M | $1.2M | $3.3M | $4.0M | $6.7M | $3.3M | $2.9M | $2.9M |
| Total operating expenses | $8.5M | $8.2M | $3.3M | $8.3M | $32.4M | $2.1M | $7.1M | $7.5M | $13.1M | $3.4M | $3.2M | $9.7M |
| Operating income | −$8.2M | −$8.4M | −$4.1M | −$8.9M | −$71.9M | −$2.1M | −$3.3M | −$3.2M | $286,000 | −$282,000 | −$4.7M | −$3.2M |
| Interest expense | $1.3M | $1.0M | $639,000 | $802,000 | $538,000 | $575,000 | $561,000 | $495,000 | $871,000 | $589,000 | $239,000 | $125,000 |
| Income before taxes | −$20.3M | $9.2M | −$9.4M | −$10.0M | −$44.5M | $12.3M | −$3.6M | −$4.1M | −$1.1M | −$1.4M | −$5.5M | −$4.0M |
| Income taxes | — | $114,000 | $5,000 | $16,000 | −$141,000 | −$394,000 | $91,000 | $129,000 | $172,000 | $25,000 | $11,000 | $1,000 |
| Net income | −$20.4M | $9.1M | −$8.9M | −$9.8M | −$34.4M | $12.7M | −$4.1M | −$4.3M | −$1.3M | −$1.4M | −$5.5M | −$4.0M |
| EBITDA | −$18.6M | −$7.7M | −$8.0M | −$8.8M | −$37.1M | −$2.1M | −$2.7M | −$2.6M | $936,000 | −$818,000 | −$4.7M | −$3.4M |
| EPS (diluted) | — | −$1.93 | −$0.23 | −$0.21 | — | −$4.30 | −$1.50 | −$0.17 | −$1.16 | −$0.50 | −$2.20 | −$1.60 |
| Gross margin | 262.8% | −68.6% | −304.5% | −437.6% | — | −26.4% | 53.7% | 61.4% | 100.4% | 43.1% | −21.5% | 90.1% |
| Operating margin | −2,714.6% | −2,419.0% | −1,653.7% | −6,297.9% | — | −1,892.7% | −47.7% | −45.5% | 2.1% | −3.5% | −65.7% | −44.9% |
| Net margin | −6,769.4% | 2,628.2% | −3,619.5% | −6,925.5% | — | 11,502.7% | −59.2% | −60.5% | −9.3% | −17.6% | −76.3% | −55.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ORGS's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ORGS financial results
In fiscal year 2024 (ended December 31, 2024), Orgenesis reported revenue of $1.0 million, up 95.3% from the year before. It had a net loss of $48.2 million, a net profit margin of −4,653.6%. Diluted earnings per share came to −$9.31. Over five years revenue grew at an average rate of −50.0% a year.
See the ORGS stock overview for the latest quote and news, or the ORGS chart for price history and technical indicators.
ORGS income statement FAQ
What is Orgenesis's annual revenue?
Orgenesis reported total revenue of $1.0 million for fiscal year 2024, which ended on December 31, 2024. That was up 95.3% from $0.5 million the previous year.
Is Orgenesis profitable?
No. Orgenesis reported a net loss of $48.2 million in fiscal 2024, a net profit margin of −4,653.6%; its operating margin was −2,518.4%.
What is Orgenesis's gross margin?
Orgenesis's gross margin was −818.6% in fiscal 2024: for every $100 of revenue, Orgenesis kept $-819 after the direct cost of its products and services.
How much does Orgenesis spend on research and development?
Orgenesis spent $3.8 million on research and development in fiscal 2024, 371.4% of revenue.
How fast is Orgenesis growing?
Revenue grew −50.0% a year on average over the last five fiscal years, from $33.3 million to $1.0 million.
What are Orgenesis's earnings per share?
Orgenesis earned $-9.31 per diluted share in fiscal 2024, compared with $-1.75 a year earlier.
When does Orgenesis's fiscal year end?
Orgenesis's fiscal year ends in December. The latest annual report covers the year ended December 31, 2024.